TY - JOUR
T1 - Genetic modification of stem cells for transplantation
AU - Phillips, M. Ian
AU - Tang, Yao Liang
N1 - Funding Information:
Supported by NIH MERIT Award R37-HL027334 and NIH R01, R01-HL077602 to M. Ian Phillips.
PY - 2008/1/14
Y1 - 2008/1/14
N2 - Gene modification of cells prior to their transplantation, especially stem cells, enhances their survival and increases their function in cell therapy. Like the Trojan horse, the gene-modified cell has to gain entrance inside the host's walls and survive and deliver its transgene products Using cellular, molecular and gene manipulation techniques the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia and apoptosis. Genetic engineering to modify cells involves constructing modules of functional gene sequences. They can be simple reporter genes or complex cassettes with gene switches, cell specific promoters and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and non-viral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, neurological diseases, (including Parkinson's, Alzheimer's and spinal cord injury repair), bone defects, hemophilia, and cancer.
AB - Gene modification of cells prior to their transplantation, especially stem cells, enhances their survival and increases their function in cell therapy. Like the Trojan horse, the gene-modified cell has to gain entrance inside the host's walls and survive and deliver its transgene products Using cellular, molecular and gene manipulation techniques the transplanted cell can be protected in a hostile environment from immune rejection, inflammation, hypoxia and apoptosis. Genetic engineering to modify cells involves constructing modules of functional gene sequences. They can be simple reporter genes or complex cassettes with gene switches, cell specific promoters and multiple transgenes. We discuss methods to deliver and construct gene cassettes with viral and non-viral delivery, siRNA, and conditional Cre/Lox P. We review the current uses of gene-modified stem cells in cardiovascular disease, diabetes, neurological diseases, (including Parkinson's, Alzheimer's and spinal cord injury repair), bone defects, hemophilia, and cancer.
KW - Cancer
KW - Cre/Lox P
KW - Diabetes
KW - Heart failure
KW - MicroRNA
KW - Neurological diseases
KW - Stem cells
KW - Vigilant Vector
UR - http://www.scopus.com/inward/record.url?scp=36849043025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36849043025&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2007.08.035
DO - 10.1016/j.addr.2007.08.035
M3 - Review article
C2 - 18031863
AN - SCOPUS:36849043025
SN - 0169-409X
VL - 60
SP - 160
EP - 172
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
IS - 2
ER -